(RTTNews) - Syncona Limited (SYNC.L) agreed to buy Applied Genetic Technologies Corp. (AGTC), through a tender offer, for about $23.5 million ($0.34 per share) in cash at the closing of the transaction plus potential future aggregate cash payments of up to $50.0 million (up to $0.73 per share) pursuant to contingent value rights or CVRs.
The $0.34 per share represents a premium of about 42% and the potential for up to $1.07 per share (inclusive of the potential CVR value) represents a premium of up to about 344% over AGTC's closing stock price on October 21, 2022.
Applied Genetic said its board recommended that the shareholders of AGTC tender their shares in the tender offer once it is commenced.
The transaction was unanimously approved by AGTC's board of directors and is expected to close in the fourth quarter of 2022.
Upon the closing of the transaction, the shares of AGTC's common stock will no longer be listed on any public market. Subject to certain limited exceptions, the CVRs will be non-transferable.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
